# Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

> **NCT07016230** · PHASE2 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic/Locally Advanced Small-Cell Lung Cancer
- Metastatic/Locally Advanced Poorly Differentiated NEC
- Metastatic/Locally Advanced High-grade MTC

## Interventions

- **DRUG:** Tarlatamab

## Key facts

- **NCT ID:** NCT07016230
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-02
- **Primary completion:** 2027-04-15
- **Final completion:** 2030-01-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07016230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07016230, "Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07016230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*